Insights from recent episode analysis
Audience Interest
Podcast Focus
Publishing Consistency
Platform Reach
Insights are generated by CastFox AI using publicly available data, episode content, and proprietary models.
Most discussed topics
Brands & references
Total monthly reach
Estimated from 3 chart positions in 3 markets.
By chart position
- 🇮🇳IN · Science#1961K to 10K
- 🇸🇬SG · Science#129500 to 3K
- 🇹🇭TH · Science#134500 to 3K
- Per-Episode Audience
Est. listeners per new episode within ~30 days
1K to 8K🎙 ~2x weekly·137 episodes·Last published yesterday - Monthly Reach
Unique listeners across all episodes (30 days)
2K to 16K🇮🇳63%🇸🇬19%🇹🇭19% - Active Followers
Loyal subscribers who consistently listen
600 to 4.8K
Market Insights
Platform Distribution
Reach across major podcast platforms, updated hourly
Total Followers
—
Total Plays
—
Total Reviews
—
* Data sourced directly from platform APIs and aggregated hourly across all major podcast directories.
On the show
From 11 epsHosts
Recent guests
Recent episodes
For Oncology Nurses: Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia — Proceedings from the 2026 Annual ONS Congress
Jul 16, 2026
Unknown duration
Novel Therapies for Non-Hodgkin Lymphoma — Proceedings from a Session Held in Conjunction with the 2026 ASCO Annual Meeting
Jul 9, 2026
Unknown duration
Acute Myeloid Leukemia — Fifth Annual National General Medical Oncology Summit
Jun 28, 2026
Unknown duration
Myelofibrosis and Systemic Mastocytosis — Fifth Annual National General Medical Oncology Summit
Jun 24, 2026
Unknown duration
Multiple Myeloma — Fifth Annual National General Medical Oncology Summit
Jun 18, 2026
Unknown duration
Social Links & Contact
Official channels & resources
Official Website
Login
RSS Feed
Login
| Date | Episode | Topics | Guests | Brands | Places | Keywords | Sponsor | Length | |
|---|---|---|---|---|---|---|---|---|---|
| 7/16/26 | For Oncology Nurses: Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia — Proceedings from the 2026 Annual ONS Congress | Featuring perspectives from Dr Farrukh T Awan, Dr Brad S Kahl, Ms Robin Klebig and Ms Mollie Moran, moderated by Dr Kahl, including the following topics:Introduction: Biology of Non-Hodgkin Lymphoma (NHL) (00:00)Current Role of CD20 x CD3 Bispecific Antibodies in NHL (4:49)Role of Polatuzumab Vedotin in Diffuse Large B-Cell Lymphoma (DLBCL) (27:48)Optimal Application of Loncastuximab Tesirine for Patients with DLBCL and Follicular Lymphoma (41:43)Role of Bruton Tyrosine Kinase (BTK) Inhibitors Alone or with Anti-CD20 Antibodies for Patients with Newly Diagnosed Chronic Lymphocytic Leukemia (CLL) (1:00:43)Combining BTK Inhibitors with Bcl-2 Inhibitors (1:31:15)Current and Future Role of Noncovalent BTK Inhibitors in CLL (1:41:30)CME information and select publications | — | ||||||
| 7/9/26 | Novel Therapies for Non-Hodgkin Lymphoma — Proceedings from a Session Held in Conjunction with the 2026 ASCO Annual Meeting | Featuring perspectives from Dr Christopher Flowers, Dr Matthew Lunning, Dr Sonali M Smith and Dr Brad S Kahl, moderated by Dr Kahl, including the following topics:Rational Incorporation of CD79b-Targeted Antibody-Drug Conjugates into the Management of Newly Diagnosed and Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) — Dr Flowers (00:00)Clinical Utility of CD19-Directed Monoclonal Antibodies in the Treatment of DLBCL and Follicular Lymphoma (FL) — Dr Smith (31:41)Optimal Use of CD19-Directed Antibody-Drug Conjugates for R/R DLBCL and FL — Dr Lunning (01:03:23)Current and Future Role of Bruton Tyrosine Kinase Inhibition in Therapy for Non-Hodgkin Lymphoma — Dr Kahl (01:26:48)CME information and select publications | — | ||||||
| 6/28/26 | Acute Myeloid Leukemia — Fifth Annual National General Medical Oncology Summit | Featuring perspectives from Dr Courtney D DiNardo and Dr Harry Paul Erba, including the following topics:Introduction (0:00)Current Management Approaches for FLT3- and IDH-Mutated Acute Myeloid Leukemia (AML) — Dr DiNardo (9:44)Current and Future Role of Menin Inhibitors for Patients with AML — Dr Erba (32:07)CME information and select publications | — | ||||||
| 6/24/26 | Myelofibrosis and Systemic Mastocytosis — Fifth Annual National General Medical Oncology Summit | Featuring perspectives from Dr Anthony M Hunter and Dr Abdulraheem Yacoub, including the following topics:Introduction (0:00)Systemic Mastocytosis — Dr Hunter (9:33)Myelofibrosis — Dr Yacoub (29:40)CME information and select publications | — | ||||||
| 6/18/26 | Multiple Myeloma — Fifth Annual National General Medical Oncology Summit | Featuring perspectives from Dr Hans Lee and Dr Noopur Raje, including the following topics:Introduction (0:00)Integrating Chimeric Antigen Receptor T-Cell Therapy and Bispecific Antibodies into the Management of Relapsed/Refractory Multiple Myeloma (R/R MM) — Dr Raje (4:30)Antibody-Drug Conjugates and Other Emerging Therapies for R/R MM — Dr Lee (28:33)CME information and select publications | — | ||||||
| 6/16/26 | Chronic Lymphocytic Leukemia — Fifth Annual National General Medical Oncology Summit | Featuring perspectives from Dr John N Allan and Dr Adam Kittai, including the following topics:Introduction (0:00)Current Management of Newly Diagnosed Chronic Lymphocytic Leukemia — Dr Allan (8:47)Noncovalent Bruton Tyrosine Kinase Inhibitors and Other Novel Strategies — Dr Kittai (38:14)CME information and select publications | — | ||||||
| 6/15/26 | Diffuse Large B-Cell Lymphoma and Follicular Lymphoma — Fifth Annual National General Medical Oncology Summit | Featuring perspectives from Dr Manali Kamdar, Dr Krish Patel and Dr Gilles Salles, including the following topics:Introduction (0:00)Antibody-Drug Conjugates and Other Novel Strategies for the Management of Diffuse Large B-Cell Lymphoma (DLBCL) — Prof Salles (7:05)Current and Future Role of Monoclonal and Bispecific Antibodies in the Management of DLBCL — Dr Patel (26:21)Chimeric Antigen Receptor (CAR) T-Cell Therapy for DLBCL — Dr Kamdar (43:12)CAR T-Cell Therapy for Follicular Lymphoma (FL) — Prof Salles (1:08:33)Other Approved and Emerging Novel Therapies for FL — Dr Patel (1:24:44)Integrating Bispecific Antibodies into the Management of FL — Dr Kamdar (1:41:34)CME information and select publications | — | ||||||
| 5/23/26 | Bruton Tyrosine Kinase InhibitorsChronic Lymphocytic Leukemia+3 | Dr Jennifer R BrownProf Wojciech Jurczak | Bruton tyrosine kinase-targeted therapyChronic Lymphocytic Leukemia | — | Bruton Tyrosine KinaseChronic Lymphocytic Leukemia+3 | — | 58m 42s | ||
| 4/20/26 | Acute Myeloid Leukemiaclinical trials+3 | Dr Amir FathiDr Eunice S Wang | Massachusetts General HospitalRoswell Park Comprehensive Cancer Center | Boston, MassachusettsBuffalo, New York | Acute Myeloid Leukemiamenin inhibitors+3 | — | 58m 54s | ||
| 4/10/26 | CELMoDsMultiple Myeloma+3 | Dr Paul G Richardson | Dana-Farber Cancer Institute | Boston, Massachusetts | CELMoDsMultiple Myeloma+3 | — | 24m 54s | ||
Want analysis for the episodes below?Free for Pro Submit a request, we'll have your selected episodes analyzed within an hour. Free, at no cost to you, for Pro users. | |||||||||
| 4/1/26 | immune thrombocytopeniaBruton tyrosine kinase inhibitors+3 | Dr Hanny Al-Samkari | Bruton tyrosine kinase inhibitorsBAFF-R antagonists+1 | — | immune thrombocytopeniaBruton tyrosine kinase inhibitors+3 | — | 24m 50s | ||
| 3/23/26 | CELMoDsMultiple Myeloma+3 | Dr Paul G Richardson | Dana-Farber Cancer Institute | Boston, Massachusetts | CELMoDsMultiple Myeloma+3 | — | 24m 29s | ||
| 3/21/26 | immune thrombocytopeniaBruton tyrosine kinase inhibitors+3 | Dr Hanny Al-Samkari | Bruton tyrosine kinase inhibitorsBAFF-R antagonists+1 | — | immune thrombocytopeniaBruton tyrosine kinase inhibitors+5 | — | 29m 16s | ||
| 3/13/26 | Acute Lymphoblastic LeukemiaBiTEs+3 | Dr Bijal Shah | Moffitt Cancer Center | Tampa, Florida | BiTEsAcute Lymphoblastic Leukemia+3 | — | 1h 03m 21s | ||
| 3/11/26 | Chronic Lymphocytic LeukemiaManagement+3 | Prof Constantine Tam | Monash University | — | Chronic Lymphocytic LeukemiaASH Annual Meeting+3 | — | 47m 10s | ||
| 3/9/26 | immune thrombocytopeniaBruton tyrosine kinase inhibitors+3 | Dr Hanny Al-Samkari | Bruton tyrosine kinase inhibitorsBAFF-R antagonists+1 | — | immune thrombocytopeniaBruton tyrosine kinase inhibitors+3 | — | 19m 21s | ||
| 3/4/26 | immune thrombocytopeniaBruton tyrosine kinase inhibitors+4 | Dr Hanny Al-Samkari | Bruton tyrosine kinase inhibitorsBAFF-R antagonists+1 | — | immune thrombocytopeniaBruton tyrosine kinase inhibitors+4 | — | 24m 25s | ||
| 2/18/26 | multiple myelomaCereblon E3 ligase modulators+3 | Dr Natalie S CallanderDr Paul G Richardson | CELMoDsUniversity of Wisconsin Carbone Cancer Center+1 | — | multiple myelomaCELMoDs+3 | — | 57m 58s | ||
| 2/13/26 | Relapsed/Refractory Multiple Myeloma — Microlearning Activity 2 with Dr Sagar Lonial: ASH 2025 Review | Dr Sagar Lonial from Winship Cancer Institute in Atlanta, Georgia, discusses recent clinical developments with BCMA-targeted therapy and investigational agents for relapsed/refractory multiple myeloma presented at ASH 2025.CME information and select publications here. | — | ||||||
| 2/6/26 | Immune Thrombocytopenia — ASH 2025 Review | Dr Hanny Al-Samkari from Massachusetts General Hospital in Boston, Dr Cindy Neunert from Columbia University Irving Medical Center in New York and Prof Francesco Zaja from ASUGI in Trieste, Italy discuss cases of immune thrombocytopenia and recent findings from the 2025 ASH Annual Meeting.CME information and select publications here. | — | ||||||
| 2/3/26 | Relapsed/Refractory Multiple Myeloma — Microlearning Activity 1 with Dr Sagar Lonial: ASH 2025 Review | Dr Sagar Lonial from Winship Cancer Institute in Atlanta, Georgia, discusses recent clinical developments with BCMA-targeted therapy and investigational agents for relapsed/refractory multiple myeloma presented at ASH 2025.CME information and select publications here. | — | ||||||
| 1/21/26 | Bispecific Antibodies in the Management of Lymphoma — ASH 2025 Review | Prof Michael Dickinson from Peter MacCallum Cancer Centre in Melbourne, Australia, and Dr Laurie H Sehn from the University of British Columbia in Vancouver, Canada, discuss clinical cases and recent findings from the 2025 ASH Annual Meeting relating to the use of bispecific antibodies in the management of lymphoma.CME information and select publications here. | — | ||||||
| 1/16/26 | Relapsed/Refractory Multiple Myeloma — ASH 2025 Review | Dr Sagar Lonial from Winship Cancer Institute of Emory University in Atlanta, Georgia, and Dr María-Victoria Mateos from the University Hospital of Salamanca in Salamanca, Spain, discuss cases of relapsed/refractory multiple myeloma and recentresearch findings from the 2025 ASH Annual Meeting. CME information and select publications here. | — | ||||||
| 1/13/26 | Follicular Lymphoma and Diffuse Large B-Cell Lymphoma — Proceedings from a Symposium Series Preceding the 67th ASH Annual Meeting and Exposition | Dr Nancy L Bartlett from the Washington University School of Medicine, Dr John P Leonard from the Perlmutter Cancer Center, Dr Matthew Matasar from Rutgers Cancer Institute, Dr Loretta J Nastoupil from Southwest Oncology and Prof Pier Luigi Zinzani from the University of Bologna in Italy discuss recent updates on available and novel treatment strategies for follicular lymphoma and diffuse large B-cell lymphoma. CME information and select publications here. | — | ||||||
| 1/9/26 | Myelofibrosis and Systemic Mastocytosis — Proceedings from a Symposium Series Preceding the 67th ASH Annual Meeting and Exposition | Prof Claire Harrison from Guy’s and St Thomas’ NHS Foundation Trust in London, Dr Andrew T Kuykendall from Moffitt Cancer Center, Dr Stephen T Oh from the Washington University School of Medicine, Dr Jeanne Palmer from the Mayo Clinic School of Medicine and Dr Raajit K Rampal from Memorial Sloan Kettering Cancer Center discuss recent updates on available and novel treatment strategies for myelofibrosis and systemic mastocytosis.CME information and select publications here. | — | ||||||
Showing 25 of 146
Pitch Fit is a Pro feature
See how bookable this show is for guests, which brands already advertise, the per-episode ad value, and the best-fit guest and sponsor profile. The numbers are blurred on the free plan.
How readily this show books outside guests like you.
How proven this show is for host-read sponsorships.
For Guests
ProFor Advertisers
ProUpgrade to Pro to unlock guest cadence, sponsor categories, fit scores, and per-episode ad value for this show.
Similar Audience Demographics
Podcasts that attract a similar listener profile
Two Onc Docs
Sam and Karine
ASCO Daily News
American Society of Clinical Oncology (ASCO)
Blood Cancer Talks
Rajshekhar Chakraborty, Ashwin Kishtagari, and Edward Cliff
Blood Podcast
American Society of Hematology
The Hematologist
The Hematologist
Gastrointestinal Cancer Update
Dr. Neil Love
WolverHeme Happy Hour
Bernard Marini, Anthony Perissinotti, et al.
Chart history for Hematologic Oncology Update
Peaked at #129 in SG, currently #129 in SG.
| Market | Genre | Peak | Current | Trend |
|---|---|---|---|---|
| SG | — | #129 | #129 | — |
| TH | — | #134 | #134 | — |
| India | — | #196 | #196 | — |
Chart Positions
3 placements across 3 markets.
Chart Positions
3 placements across 3 markets.